1 reports of this reaction
1.9% of all APIS MELLIFERA reports
#10 most reported adverse reaction
BIOPSY LIVER ABNORMAL is the #10 most commonly reported adverse reaction for APIS MELLIFERA, manufactured by Boiron. There are 1 FDA adverse event reports linking APIS MELLIFERA to BIOPSY LIVER ABNORMAL. This represents approximately 1.9% of all 52 adverse event reports for this drug.
Patients taking APIS MELLIFERA who experience biopsy liver abnormal should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BIOPSY LIVER ABNORMAL is a less commonly reported adverse event for APIS MELLIFERA, but still significant enough to appear in the safety profile.
In addition to biopsy liver abnormal, the following adverse reactions have been reported for APIS MELLIFERA:
BIOPSY LIVER ABNORMAL has been reported as an adverse event in 1 FDA reports for APIS MELLIFERA. This does not prove causation, but indicates an association observed in post-market surveillance data.
BIOPSY LIVER ABNORMAL accounts for approximately 1.9% of all adverse event reports for APIS MELLIFERA, making it a notable side effect.
If you experience biopsy liver abnormal while taking APIS MELLIFERA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.